who should not take glp 1 receptor agonists Trends in the Development of GLP-1 GLP-1 Receptor Agonists and Research

To balance risks and benefits, expert opinions emphasize the importance of individualized dosing, shared decision-making, and careful patient selection

Semaglutide is not appropriate for everyone

GLP-1 effects on -cell proliferation and apoptosis The prevalence of type 2 diabetes correlates with excess body weight and also increases with age [525]

Bit of Background These new classes of antiobesity medications (ie, the GLP-1 agonists and dual agonists), referred to in this article as weight management medications, arent really new.1-4 The basic science and pharmaceutical research and development to bring these to market began more than two decades ago when two scientists, Matthias Tschop, MD, and Richard DiMarchi, PhD, hypothesized that the actions of various gut hormones may offer safe and unprecedented weight loss

Accurate this is the core mechanism